Q-omics provides the consensus-scored ZAR1 profile across patient tissues and cancer cell-line models. ZAR1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZAR1 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, ZAR1 RNA expression shows 13,423 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, COAD, and THYM as cancer lineages where ZAR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZAR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZAR1 survival associations across molecular data types. ZAR1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZAR1 RNA expression–survival associations across cancer types. High ZAR1 expression shows unfavorable associations in MESO, LGG, LIHC and SARC, but favorable associations in UVM and THCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZAR1 RNA expression.
This table summarizes ZAR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZAR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZAR1 shows lower tumor expression in LUAD and LUSC and higher tumor expression in COAD, THCA, HNSC and BRCA. The COAD box plot shows higher ZAR1 RNA expression in tumor versus normal tissue (log2 FC = +0.058, t-test p = .007).
This table shows molecular features associated with ZAR1 in patient tissues and cancer cell lines. In patient samples, ZAR1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZAR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
